BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

313 related articles for article (PubMed ID: 32625208)

  • 21. Distinct Cell Adhesion Signature Defines Glioblastoma Myeloid-Derived Suppressor Cell Subsets.
    Bayik D; Bartels CF; Lovrenert K; Watson DC; Zhang D; Kay K; Lee J; Lauko A; Johnson S; Lo A; Silver DJ; McGraw M; Grabowski M; Mohammadi AM; Veglia F; Fan Y; Vogelbaum MA; Scacheri P; Lathia JD
    Cancer Res; 2022 Nov; 82(22):4274-4287. PubMed ID: 36126163
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Immunosuppressive Myeloid Cells' Blockade in the Glioma Microenvironment Enhances the Efficacy of Immune-Stimulatory Gene Therapy.
    Kamran N; Kadiyala P; Saxena M; Candolfi M; Li Y; Moreno-Ayala MA; Raja N; Shah D; Lowenstein PR; Castro MG
    Mol Ther; 2017 Jan; 25(1):232-248. PubMed ID: 28129117
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Tumor cell and immune cell profiles in primary human glioblastoma: Impact on patient outcome.
    González-Tablas Pimenta M; Otero Á; Arandia Guzman DA; Pascual-Argente D; Ruíz Martín L; Sousa-Casasnovas P; García-Martin A; Roa Montes de Oca JC; Villaseñor-Ledezma J; Torres Carretero L; Almeida M; Ortiz J; Nieto A; Orfao A; Tabernero MD
    Brain Pathol; 2021 Mar; 31(2):365-380. PubMed ID: 33314398
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Immunosuppression by monocytic myeloid-derived suppressor cells in patients with pancreatic ductal carcinoma is orchestrated by STAT3.
    Trovato R; Fiore A; Sartori S; Canè S; Giugno R; Cascione L; Paiella S; Salvia R; De Sanctis F; Poffe O; Anselmi C; Hofer F; Sartoris S; Piro G; Carbone C; Corbo V; Lawlor R; Solito S; Pinton L; Mandruzzato S; Bassi C; Scarpa A; Bronte V; Ugel S
    J Immunother Cancer; 2019 Sep; 7(1):255. PubMed ID: 31533831
    [TBL] [Abstract][Full Text] [Related]  

  • 25. LILRB4 promotes tumor metastasis by regulating MDSCs and inhibiting miR-1 family miRNAs.
    Su MT; Kumata S; Endo S; Okada Y; Takai T
    Oncoimmunology; 2022; 11(1):2060907. PubMed ID: 35402083
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Asah2 Represses the p53-Hmox1 Axis to Protect Myeloid-Derived Suppressor Cells from Ferroptosis.
    Zhu H; Klement JD; Lu C; Redd PS; Yang D; Smith AD; Poschel DB; Zou J; Liu D; Wang PG; Ostrov D; Coant N; Hannun YA; Colby AH; Grinstaff MW; Liu K
    J Immunol; 2021 Mar; 206(6):1395-1404. PubMed ID: 33547170
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Inhibiting myeloid-derived suppressor cell trafficking enhances T cell immunotherapy.
    Sun L; Clavijo PE; Robbins Y; Patel P; Friedman J; Greene S; Das R; Silvin C; Van Waes C; Horn LA; Schlom J; Palena C; Maeda D; Zebala J; Allen CT
    JCI Insight; 2019 Apr; 4(7):. PubMed ID: 30944253
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Pancreatic adenocarcinoma up-regulated factor (PAUF) enhances the accumulation and functional activity of myeloid-derived suppressor cells (MDSCs) in pancreatic cancer.
    Song J; Lee J; Kim J; Jo S; Kim YJ; Baek JE; Kwon ES; Lee KP; Yang S; Kwon KS; Kim DU; Kang TH; Park YY; Chang S; Cho HJ; Kim SC; Koh SS; Kim S
    Oncotarget; 2016 Aug; 7(32):51840-51853. PubMed ID: 27322081
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Role of macrophage migration inhibitory factor in primary glioblastoma multiforme cells.
    Baron N; Deuster O; Noelker C; Stüer C; Strik H; Schaller C; Dodel R; Meyer B; Bacher M
    J Neurosci Res; 2011 May; 89(5):711-7. PubMed ID: 21360573
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Visualization and quantification of
    Hoffmann SHL; Reck DI; Maurer A; Fehrenbacher B; Sceneay JE; Poxleitner M; Öz HH; Ehrlichmann W; Reischl G; Fuchs K; Schaller M; Hartl D; Kneilling M; Möller A; Pichler BJ; Griessinger CM
    Theranostics; 2019; 9(20):5869-5885. PubMed ID: 31534525
    [TBL] [Abstract][Full Text] [Related]  

  • 31. MIF Is Necessary for Late-Stage Melanoma Patient MDSC Immune Suppression and Differentiation.
    Yaddanapudi K; Rendon BE; Lamont G; Kim EJ; Al Rayyan N; Richie J; Albeituni S; Waigel S; Wise A; Mitchell RA
    Cancer Immunol Res; 2016 Feb; 4(2):101-12. PubMed ID: 26603621
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Targeted Deletion of CXCR2 in Myeloid Cells Alters the Tumor Immune Environment to Improve Antitumor Immunity.
    Yang J; Yan C; Vilgelm AE; Chen SC; Ayers GD; Johnson CA; Richmond A
    Cancer Immunol Res; 2021 Feb; 9(2):200-213. PubMed ID: 33177110
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Ibudilast sensitizes glioblastoma to temozolomide by targeting Macrophage Migration Inhibitory Factor (MIF).
    Ha W; Sevim-Nalkiran H; Zaman AM; Matsuda K; Khasraw M; Nowak AK; Chung L; Baxter RC; McDonald KL
    Sci Rep; 2019 Feb; 9(1):2905. PubMed ID: 30814573
    [TBL] [Abstract][Full Text] [Related]  

  • 34. IL15 modification enables CAR T cells to act as a dual targeting agent against tumor cells and myeloid-derived suppressor cells in GBM.
    Zannikou M; Duffy JT; Levine RN; Seblani M; Liu Q; Presser A; Arrieta VA; Chen CJ; Sonabend AM; Horbinski CM; Lee-Chang C; Miska J; Lesniak MS; Gottschalk S; Balyasnikova IV
    J Immunother Cancer; 2023 Feb; 11(2):. PubMed ID: 36759014
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Leukocyte immunoglobulin-like receptors in human diseases: an overview of their distribution, function, and potential application for immunotherapies.
    Zhang J; Mai S; Chen HM; Kang K; Li XC; Chen SH; Pan PY
    J Leukoc Biol; 2017 Aug; 102(2):351-360. PubMed ID: 28351852
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Myeloid-Derived Suppressor Cells Impair B Cell Responses in Lung Cancer through IL-7 and STAT5.
    Wang Y; Schafer CC; Hough KP; Tousif S; Duncan SR; Kearney JF; Ponnazhagan S; Hsu HC; Deshane JS
    J Immunol; 2018 Jul; 201(1):278-295. PubMed ID: 29752311
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The New Era of Cancer Immunotherapy: Targeting Myeloid-Derived Suppressor Cells to Overcome Immune Evasion.
    De Cicco P; Ercolano G; Ianaro A
    Front Immunol; 2020; 11():1680. PubMed ID: 32849585
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Chemokines and their receptors promoting the recruitment of myeloid-derived suppressor cells into the tumor.
    Li BH; Garstka MA; Li ZF
    Mol Immunol; 2020 Jan; 117():201-215. PubMed ID: 31835202
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Early Posttransplant Mobilization of Monocytic Myeloid-derived Suppressor Cell Correlates With Increase in Soluble Immunosuppressive Factors and Predicts Cancer in Kidney Recipients.
    Utrero-Rico A; Laguna-Goya R; Cano-Romero F; Chivite-Lacaba M; Gonzalez-Cuadrado C; Rodríguez-Sánchez E; Ruiz-Hurtado G; Serrano A; Fernández-Ruiz M; Justo I; González E; Andrés A; Paz-Artal E
    Transplantation; 2020 Dec; 104(12):2599-2608. PubMed ID: 32068661
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Tumor conditions induce bone marrow expansion of granulocytic, but not monocytic, immunosuppressive leukocytes with increased CXCR2 expression in mice.
    Bian Z; Shi L; Venkataramani M; Abdelaal AM; Culpepper C; Kidder K; Liang H; Zen K; Liu Y
    Eur J Immunol; 2018 Mar; 48(3):532-542. PubMed ID: 29120053
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.